Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) unit Shandong Zibo Xincat Pharmaceutical recently received a drug registration certificate approved by China's National Medical Products Administration for its febuxostat tablets, a Monday bourse filing said.
Febuxostat is suitable for the long-term treatment of hyperuricemia in gout patients.
Hong Kong-listed shares of the pharmaceutical company closed over 1% lower on Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。